ProphylacticLevofloxacin In Pediatric Neutropenic Patients During Autologous Hematopoietic Stem Cell Transplantation (HSCT)

Abstract

BackgroundBacterial sepsis continues to be a leading cause of morbidity and toxic death in children receiving myelosuppressive chemotherapy and for those undergoing hematopoietic stem cell transplants.Using fluoroquinolones in prophylaxis against gram negative bacterial infection is not the standard of care in neutropenic pediatric patients, and till now it is a controversial issue. This study was conducted to assess the effect of levofloxacin prophylaxis on prevention of bacterial infection and on the duration of antibiotic use during profound neutropenia in pediatric patient with hematopoietic stem cell transplantation. MethodsNon-randomized comparative study between 2 groups of pediatric neutropenic patients underwent autologous stem cell transplantation; one group didn't receive prophylactic levofloxacin (control group), the other group received prophylactic levofloxacin (10mg/kg/day) starting from the first day of the conditioning till engraftment or 1stspike of fever. ResultsA total of 96 patients who underwent autologous stem cell transplantation were analyzed (46 patients in the control group and 50 patients taking levofloxacin). The median duration till onset of 1stfever was 11 days from the beginning of conditioning regimen in the control group as compared to 15 days in patients who were receiving levofloxacin, (p ≤ 0.001). Both groups had the same rate of bacteremia (30%) but the percentage of gram negative infections was higher in the control group (50%) as compared to (20%) in levofloxacin group, also the incidence of bacterial sepsis was higher in patients without levofloxacin (4/46) than those with levofloxacin (1/50). The median duration of antibiotic use was significantly lower in the levofloxacin group (10 days) as compared with (14 days) in patients on control group, (p <0.001). ConclusionLevofloxacin use can decrease the incidence of the gram negative bacteremia and their septic complications and will shorten the duration of antibiotic use, but its impact on emergence of resistant organisms should be closely monitored. Disclosures:No relevant conflicts of interest to declare.